Vitasora Health Limited · ASX:VHL
Vitasora Health — Merger or Acquisition (June 2023)
25 slides from Vitasora Health's merger presentation, Jun 7, 2023
Slide 1: Respiri x ACCESS Telehealth
ASX: RSH OTCQB: RSHUF Respiri x ACCESS Telehealth An integrated, scalable and proven growth engine to deliver remote patient monitoring (RPM) solutions to the US healthcare market Marjan Mikel (CEO) June 2023 1
Slide 2: The ACCESS acquisition at a glance
The ACCESS acquisition at a glance Unlocking revenue growth and scale through a turnkey RPM solution 2
Slide 3: Respiri x ACCESS
Respiri x ACCESS Diversified and integrated RPM delivery with wheezo® at the forefront Strategic acquisition snapshot • Respiri to acquire ACCESS Enhanced Growth Proven delivery telehealth, a leading US-based RPM economics opportunities team provider for US$1.5m. Significant revenue Multiplies total
Slide 4: On track to achieve our vision
On track to achieve our vision Becoming a leading end-to-end RPM provider Respiri today Future state An eHealth SAAS company A diversified RPM provider with an supporting respiratory health integrated solution management • Combining in-house IP with other • Growing adoption of medical device RPM ser
Slide 5: The ACCESS acquisition in detail
The ACCESS acquisition in detail Unlocking revenue growth and scale through a turnkey RPM solution 5
Slide 6: A transformational acquisition
A transformational acquisition An end-to-end RPM solution Growing revenue and margins Scalable infrastructure Meet known demand for RPM across all Improved margins from US$10-$20 per Provides clinical staff and services with high-risk disease types, not just patient for wheezo® device sales to $70-
Slide 7: A transformational acquisition
A transformational acquisition Accelerating growth and pipeline The team to deliver RPM market set to grow at an annual rate Board and management have proven of 30%+ to US$85Bn by 2026. sector experience with large healthcare and SaaS transactions. 10 customers across 14 US states utilizing wheezo;
Slide 8: wheezo® – An ongoing differentiator and strategic advantage
wheezo® – An ongoing differentiator and strategic advantage • Provides an objective and accurate method for assessing wheeze3 • A first easy to use device for respiratory – underpinning RPM Health Status Recording… Tool A simple questionnaire to review the level of impact. Algorithm detects wheeze r
Slide 9: A threefold expansion of the total addressable US market
A threefold expansion of the total addressable US market Post-acquisition Expand to service demand for RPM related to a broader set of high-risk disease types (e.g. cardiovascular, diabetes and obesity) Respiri today Respiratory health management Delivered through: Unique wheezo® FDA approved medi
Slide 10: Expanding our share of the high-growth RPM market
Expanding our share of the high-growth RPM market A growth opportunity Centres for Medicare & Medicaid that benefits healthcare Services (CMS) reimburse RPM across all of USA organizations and patients The opportunity US payors understand and fund • RPM market has a CAGR of 30%+ preventative medicin
Slide 11: Significantly increasing monthly recurring revenue backed by reimbursements
Significantly increasing monthly recurring revenue backed by reimbursements The ACCESS acquisition increases revenue per patient per month from ~US$10-$20 to ~US$70-$100 That uplift is supported by: RPM is generously reimbursed RPM reimbursement due to Reimbursements generate proven benefits signifi
Slide 12: Significantly increasing monthly recurring revenue backed by reimbursements
Significantly increasing monthly recurring revenue backed by reimbursements Pre-acquisition CPT code linked to wheezo medical device = ~US$10-$20 per patient per + Post-acquisition additional CPT codes available to Respiri to = ~US$70-$100 per patient per month grow ARPU month Remote patient monitor
Slide 13: Why reimbursement-backed revenue growth is sustainable
Why reimbursement-backed revenue growth is sustainable 123% IMPROVEMENT IN MEDICARE (CMS) AVERAGE PROGRAM COMPLIANCE ROLLING 12 COMPARED TO MEDICARE MONTHS 4.34 MONTHS ACCESS RPM AVERAGE 9.6 MONTHS • ACCESS has a demonstrated ability to keep patients persistent on programs and improve patient outcom
Slide 14: Model already validated with existing customers
Model already validated with existing customers wheezo® led sale with expansion into broader patient cohorts The HCO The challenge The opportunity The solution Arkansas Heart Hospital AHH not achieving 30-day re- ACCESS secured AHH as a wheezo® led RPM program to (AHH) is a 112-bed facility admissio
Slide 15: What ACCESS brings
What ACCESS brings The people, processes and technology to deliver best-in- class RPM delivery 15
Slide 16: Achieving best-in-class RPM delivery
Achieving best-in-class RPM delivery How Respiri and ACCESS exemplify a superior RPM delivery platform Easy-to-use devices Delivered through wheezo and other freely available devices Platform to share data with ACCESS’s telehealth RPM platform Remotli integrated with Respiri’s healthcare professiona
Slide 17: Proven RPM commercialization experience
Proven RPM commercialization experience We have highly experienced RPM leaders that can deliver • CEO Marjan Mikel led Health Sleep Solutions (HSS) to 40% market share in Australia's sleep apnea RPM industry. • Mikel secured ResMed as a cornerstone investor before facilitating a sale to French multi
Slide 18: Our US journey and footprint
Our US journey and footprint Track record of commercialisation with scalable pipeline 18
Slide 19: US commercialisation achieved
US commercialisation achieved Clinical and RPM program US market Commercial RPM program regulatory design proven requirements pipeline roll-out • FDA approved Class II • Patients highly • Qualifies for CMS RPM • 10 Health Care • End to End RPM device (wheezo®) compliant CPT code Organisation (HCO) s
Slide 20: Strong progress made in large US market
Strong progress made in large US market Full wheezo RPM patient Full wheezo RPM program patient onboarding commenced in Contract secured with a onboarding commencing in Michigan Arkansas Heart Hospital and Onboarding of new major home and Children's Hospital (Part of the NYSE- North Carolina Healthc
Slide 21: Established customer base and a growing pipeline of opportunities
Established customer base and a growing pipeline of opportunities New York (major teaching Illinois hospital) + FQHC (Home Health services) Minnesota Lung Center (Resp Specialist Centre) Michigan Detroit Childrens (Pulmonology) Pennsylvania (home health services) +100 Resp clinics across West Virgin
Slide 22: Near-term growth drivers
Near-term growth drivers Poised to accelerate a significant US opportunity Enhanced economics Growth opportunities Proven delivery team • Significant revenue upside supported • Multiplies total addressable market • Board and Exec team with track- by reimbursements and expands into RPM for new record
Slide 23: Forward looking
Forward looking Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and a
Slide 24: Appendix 1: Leadership team: proven track record
Appendix 1: Leadership team: proven track record Marjan Mikel Peter Hildebrandt George Vlachodimitropoulos Chief Executive Officer & Chief Operations Officer Chief Technology Officer Managing Director Global and USA experienced with 35 years in MBA-educated, internationally experienced business Tech
Slide 25: Appendix 2: Ongoing R&D
Appendix 2: Ongoing R&D On track with strong support from our MAB Medical Advisory Board Current status • William S. Krimsky, FCCP, DAABIP (Chair) • Finalising initial protocol to begin validating • Professor Gerard J. Criner, MD, FACP, FACCP Respiri’s Phase 1 physiological metrics • Ass. Professor